Semaglutide is one of the most effective weight loss medications available. In the landmark STEP 1 clinical trial, participants lost an average of 14.9% of their body weight over 68 weeks. For someone weighing 230 pounds, that translates to roughly 34 pounds. It works, but it comes with real tradeoffs worth understanding before you start.
How Semaglutide Causes Weight Loss
Semaglutide mimics a hormone your body naturally produces called GLP-1 (glucagon-like peptide-1). This hormone is released after you eat and signals your brain that you’re full. The medication is a modified version that lasts much longer in your body than the natural hormone, which breaks down within minutes.
The drug works through two main pathways. First, it acts directly on your brain’s appetite control center in the hypothalamus. It activates neurons that make you feel full while simultaneously quieting the neurons that drive hunger. The result is a genuine reduction in appetite, not just willpower. People on semaglutide consistently report thinking about food less, feeling satisfied with smaller portions, and losing interest in snacking between meals.
Second, semaglutide slows down how quickly your stomach empties after a meal. Food sits in your stomach longer, which physically extends the feeling of fullness. This combination of reduced appetite signals in the brain and slower digestion is what makes the drug so effective compared to older weight loss medications that typically targeted only one pathway.
What the Clinical Trials Show
The STEP 1 trial, which tested the 2.4 mg weekly injection in adults with obesity or overweight (but without type 2 diabetes), produced the 14.9% average weight loss figure that put semaglutide on the map. That was measured at 68 weeks, roughly 16 months, compared to just 2.4% in the placebo group. Participants in both groups also followed a reduced-calorie diet and increased their physical activity, so the drug’s effect was on top of lifestyle changes.
Not everyone responds equally. Some people lose 20% or more of their body weight, while others lose closer to 5%. The reasons for this variation aren’t fully understood, but individual biology, adherence to the medication schedule, and lifestyle factors all play a role. Weight loss typically begins within the first few weeks and accelerates as the dose gradually increases over the first four to five months.
How It Compares to Tirzepatide
A head-to-head trial published in the New England Journal of Medicine compared semaglutide directly against tirzepatide (sold as Zepbound for weight loss). At 72 weeks, tirzepatide produced 20.2% body weight loss versus 13.7% for semaglutide. Tirzepatide also shrank waist circumference by about 7 inches compared to 5 inches with semaglutide. Participants on tirzepatide were more likely to reach every weight loss milestone, whether that was 10%, 15%, 20%, or 25% of their starting weight.
Tirzepatide works on two gut hormones instead of one, which likely explains the difference. That said, semaglutide has a longer track record, more published safety data, and remains highly effective in its own right. Both drugs represent a significant leap over anything previously available for weight management.
Side Effects to Expect
Gastrointestinal problems are the most common side effects by a wide margin. In clinical trials, about 44% of people on semaglutide experienced nausea, 30% had diarrhea, roughly 25% dealt with vomiting, and 24% reported constipation. These numbers are notably higher than the placebo group (where 16% had nausea, for instance), confirming that the drug itself is responsible.
The good news is that these side effects are typically mild to moderate and tend to fade over time. They’re most common during the dose escalation phase, when your body is adjusting to increasing amounts of the medication. This is why the standard protocol starts at a low dose and ramps up gradually over several months. Eating smaller meals, avoiding greasy foods, and staying hydrated can help manage symptoms during this period.
The FDA has also issued a boxed warning based on animal studies showing a risk of thyroid C-cell tumors. This type of cancer has not been confirmed in humans taking semaglutide, but the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a rare genetic condition called multiple endocrine neoplasia syndrome type 2.
What Happens When You Stop
This is the part that catches many people off guard. In the STEP 1 trial extension, researchers tracked participants for a year after they stopped taking semaglutide. On average, they regained about two-thirds of the weight they had lost. Specifically, participants who had been on semaglutide regained 11.6 percentage points of body weight, leaving them with a net loss of only 5.6% from their original starting weight at the two-year mark. Weight regain continued throughout the entire follow-up period with no sign of leveling off.
This isn’t a failure of the drug so much as a reflection of how obesity works. The biological signals that drive hunger and slow metabolism don’t reset after weight loss. When the medication is removed, those signals reassert themselves. For this reason, semaglutide is approved as a chronic, long-term treatment rather than a short course. Most people who want to maintain their results will need to stay on the medication indefinitely, similar to how blood pressure medication manages hypertension without curing it.
Who Can Get a Prescription
The FDA approved semaglutide for weight management (under the brand name Wegovy) for adults with a BMI of 30 or greater, which qualifies as obesity. Adults with a BMI of 27 or greater can also qualify if they have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. It’s approved as an add-on to a reduced-calorie diet and increased physical activity, not as a standalone treatment.
What It Costs
Cost remains a significant barrier. With commercial insurance that covers the drug, Novo Nordisk offers a savings program that can bring the copay down to as little as $25 per month. Without insurance coverage, the self-pay price starts at $149 per month for the lower maintenance doses. Coverage varies widely between insurance plans, and many plans still don’t cover weight loss medications at all. Novo Nordisk’s patient support program, NovoCare, can help you check whether your specific plan covers Wegovy before you commit.
Given that semaglutide is designed as a long-term medication, cost adds up quickly. If you’re considering it, verifying insurance coverage early in the process can save you from starting a medication you may not be able to afford to continue, which, as the weight regain data shows, would likely mean losing most of the benefit.